Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 3 records in total 3
    records per page




    The Diagnostic Trap Occurred in Two COVID-19 Cases Combined Pneumocystis Pneumonia MESHD Pneumonia HP in Patient with AIDS MESHD

    Authors: Wei Guo; Maomao Wang; Fangzhao Ming; Weiming Tang; Ke Liang

    doi:10.21203/rs.3.rs-53350/v1 Date: 2020-08-04 Source: ResearchSquare

    Background : The limited knowledge on the diagnosis of Coronavirus disease MESHD 2019 (COVID-19) at the early stage of the pandemic may lead to misdiagnoses, especially when the nucleic acid inspection cannot meet the mass requirement. This condition is even actual for people who are living with HIV MESHD/ AIDS MESHD (PLWHA), for the latter is vulnerable to variable infections. Case Presentation : In this short communication, we introduced two HIV infected MESHD individuals who had PCP but was misdiagnosed as COVID-19 initially, and finally infected with SARS-CoV-2 in hospital in Wuhan, China. Eventually, both patients improved soon after they were switched to the treatment of SMZ/TMP.Conclusions : We suggested that the hospitalized COVID-19 cases should be screened with HIV MESHD and other pathogens, to prevent that PLWHA who have PCP from being misdiagnosed as COVID-19.

    Comparison of initial HRCT features of COVID-19 pneumonia HP pneumonia MESHD and other viral pneumonias MESHD pneumonias HP

    Authors: Yilong Huang; Yuanming Jiang; Li Wu; Wenfang Yi; Jiyao Ma; Peng Wang; Ying Xie; Zhipeng Li; Xiang Li; Minchang Hong; Jialong Zhou; Chuwei Duan; Yunhui Yang; Wei Zhao; Feng Yuan; Dan Han; Bo He

    doi:10.21203/rs.3.rs-29527/v1 Date: 2020-05-17 Source: ResearchSquare

    Background: Multicenter retrospective comparison of the first high-resolution computed tomography (HRCT) findings of coronavirus disease MESHD 2019 (COVID-19) and other viral pneumonias MESHD pneumonias HP.Methods: We retrospectively collected clinical and imaging data from 254 cases of confirmed TRANS viral pneumonia MESHD pneumonia HP in 20 hospitals in Yunnan Province, China, from March 1, 2015, to March 15, 2020. According to the virus responsible for the pneumonia HP pneumonia MESHD, the pneumonias HP pneumonias MESHD were divided into non-COVID-19 (133 cases) and COVID-19 (121 cases). The non-COVID-19 pneumonias HP pneumonias MESHD included 3 types: cytomegalovirus (CMV) (31 cases), influenza A virus (82 cases), and influenza B virus (20 cases). The differences in the basic clinical characteristics, lesion distribution, location and imaging signs among the four viral pneumonias HP pneumonias MESHD were analyzed and compared.Results: Fever HP Fever MESHD and cough HP cough MESHD were the most common clinical symptoms of the four viral pneumonias HP pneumonias MESHD. Compared with the COVID-19 patients, the non-COVID-19 patients had higher proportions of fatigue HP fatigue MESHD, sore throat, expectorant and chest tightness HP chest tightness MESHD (all p<0.000). In addition, in the CMV pneumonia MESHD pneumonia HP patients, the proportion of patients with combined acquired immunodeficiency HP immunodeficiency MESHD syndrome ( AIDS MESHD) and leukopenia HP leukopenia MESHD were high (all p<0.000). Comparisons of the imaging findings of the four viral pneumonias HP pneumonias MESHD showed that pulmonary lesions of COVID-19 were more likely to occur in the peripheral and lower lobes of both lungs, while those of CMV pneumonia MESHD pneumonia HP were diffusely distributed. Compared with the non-COVID-19 pneumonias HP pneumonias MESHD, COVID-19 pneumonia HP pneumonia MESHD was more likely to present as ground-glass opacity (GGO), intralobular interstitial thickening HP, vascular thickening and halo sign (all p<0.05). In addition, in the early stage of COVID-19, extensive consolidation, fibrous stripes, subpleural lines, crazy-paving pattern, tree-in-bud HP, mediastinal lymphadenectasis, pleural thickening HP pleural thickening MESHD and pleural effusion HP pleural effusion MESHD were rare (all p<0.05).Conclusion: The HRCT findings of COVID-19 pneumonia HP pneumonia MESHD and other viral pneumonias MESHD pneumonias HP overlapped significantly, but many important differential imaging features could still be observed.

    Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma SERO virus inactivation method for blood SERO safety and convalescent plasma SERO therapy for the COVID-19 outbreak

    Authors: Changzhong Jin; Bin Yu; Jie Zhang; Hao Wu; Xipeng Zhou; Hangping Yao; Fumin Liu; Xiangyun Lu; Linfang Cheng; Miao Jiang; Nanping Wu

    doi:10.21203/rs.3.rs-17718/v1 Date: 2020-03-17 Source: ResearchSquare

    Background  With the outbreak of unknown pneumonia HP pneumonia MESHD in Wuhan, China in December 2019, a new coronavirus (SARS-CoV-2) attracted worldwide attention. Although coronaviruses typically infect the upper MESHD or lower respiratory tract, discovery of the virus in plasma SERO is common. Therefore, the risk of transmitting coronavirus through transfusion of blood SERO products remains. As more asymptomatic TRANS infections are found in COVID-19 cases, blood SERO safety is shown to be particularly important, especially in endemic areas. Study Design and MethodsBX-1, an ‘ AIDS MESHD treatment instrument’ based on methylene blue (MB) photochemical technology, developed by Boxin (Beijing) Biotechnology Development LTD, has proven that inactivation of lipid-enveloped viruses such as HIV-1 in plasma SERO has high efficiency, without damage to other components in the plasma SERO, and proved safe and reliable in clinical trials of HIV treatment. In order to confirm the inactivation effect of BX-1 in SARS-CoV-2, we used the SARS-CoV-2 virus strain isolated from Zhejiang University for plasma SERO virus inactivation studies. Results and ConclusionBX-1 can effectively eliminate SARS-CoV-2 within 2 mins, and the virus titer decline can reach 4.5 log10 TCID50/mL. Faced with the expanding epidemic, BX-1 is safe for blood SERO transfusion and plasma SERO transfusion therapy in recovery patients, and the inactivated vaccine preparation has great potential for treatment in the current outbreak.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.